Health Care • Biotechnology: Pharmaceutical Preparations
$8.11 ▼ -0.37
(-4.36%)
MKT CAP: $11.9M • VOL: 20.3K
52W L $0 52W H $16
ROARABLE / RQD
D- • 42/100
PIOTROSKI
1 / 9
ASBP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $6.2K | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | -$116 | — | — |
| Gross Margin % | -1.9% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$19.4M | -$1.2M | $0 |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | -$24.5M | -$1.3M | $4.5M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$4.9M | -$265.2K | -$653.1K |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$4.9M | -$265.2K | -$653.1K |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $1.0M | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$6.4M | -$1.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ASBP.